An observational study in Enterococcal Bacteremia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-01.
Sponsored by The University of Texas Health Science Center, Houston · Observational
Among 79 studies in Bacteremia with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Bacteremia · United States.
Among the 79 studies in Bacteremia with a site in United States, this one is the 10th largest by planned enrollment of the 32 observational ones, is one of 3 that started in 2016, is one of 32 observational ones, and was the 68th registered.
297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 300 across 125 observational studies indexed under Bacteremia.
Browse Bacteremia studies →6 of the 79 studies in Bacteremia with a site in United States are open now, in 7 countries. Each count lists the studies.
Of the 40 Bacteremia studies recruiting now, 32 (80%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →79 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2016.
Median enrollment 85 across the 45 interventional studies, 470 across the 32 observational. Of the 64 that completed or were terminated, 24 (38%) have results posted.
30 of 79 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 897 studies on the registry; 214 are open to participants now.
Of its 173 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 1 study filed under Bacteremia — fewer than ten, so there is no comparison to draw.
4 of the studies in Bacteremia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859852Deepull Diagnostics S.L.Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test | 2027-04 |
| NCT01879761University of ChicagoImmune Resolution After Staphylococcus Aureus Bacteremia | 2027-06 |
| NCT07148960West Virginia UniversityDoes Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? | 2027-07 |
| NCT05721781Wake Forest University Health SciencesReducing Risk for Infective Endocarditis | 2027-09 |
Among the 79 studies in Bacteremia with a site in United States, from their registry updates:
The purpose of this study is to assemble a multicenter prospective cohort of patients with enterococcal bloodstream infections (BSIs) to provide data on outcomes of patients with enterococcal BSIs for sample size calculations for future trials, as well as to characterize enterococcal isolates causing BSIs in order to comprehensively dissect the molecular epidemiology of infecting organisms for future studies.
Hospitalized patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
All-cause, in-hospital mortality
Death by any cause while patient is in the hospital
Time frame: 30 days or until hospital discharge
Number of participants with microbiological outcome
Eradication defined as a negative follow-up blood culture \> 4 days after index blood culture
Time frame: 7 days after first documented positive blood culture
Number of participants with recurrence of bacteremia
Positive blood culture with the same organism within the following 14 days after the documented eradication of bacteremia
Time frame: 14 days after the documented eradication of bacteremia
Started Aug 2016 (actual). Primary completion is estimated for May 2025, 105 months after the start.
Of 32 non-industry observational studies under Bacteremia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 105 months is above that.
Counting every sponsor, half of 39 studies reached it within 21 months; a quarter within 11 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →